| 1. |
- Andreasson, Ulf, 1968, et al.
(författare)
-
Method and Clinical Validation of Biomarkers for Neurodegenerative Diseases
- 2021
-
Ingår i: Cerebrospinal Fluid Biomarkers. Neuromethods, vol 168. Teunissen C.E., Zetterberg H. (eds). - New York, NY : Springer. - 0893-2336. - 9781071613184 ; , s. 163-173
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- In the Merriam-Webster dictionary, one definition of the word valid is “well-grounded or justifiable: being at once relevant and meaningful.” Validation is then the process of determining the degree of validity. From this broad definition, it follows that validations can be made in many different fields with quite different implications. When talking about validation, it is therefore important to specify the subject under scrutiny and in this chapter the focus will be on validation of biomarkers. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
|
|
| 2. |
|
|
| 3. |
- Blennow, Kaj, 1958, et al.
(författare)
-
Fluid Biomarkers in Alzheimer Disease, 91
- 2012
-
Ingår i: The biology of Alzheimer disease / edited by Dennis J. Selkoe, David M. Holtzman, and Eckhard Mandelkow.. - Cold Spring Harbor, N.Y. : Cold Spring Harbor Laboratory Press. - 9781936113446 ; , s. 91-114
-
Bokkapitel (refereegranskat)
|
|
| 4. |
- Blennow, Kaj, 1958, et al.
(författare)
-
Likvoranalyser : Del av: Sjukdomar i centrala nervsystemet
- 2012
-
Ingår i: Laurells Klinisk kemi i praktisk medicin 9., [rev. och utök.] uppl. /redaktion: Peter Nilsson-Ehle, Maria Berggren Söderlund, Elvar Theodorsson ; redaktionskommitté: Charlotte Becker, Kjell Grankvist, Anders Grubb, Göran Lindstedt, Per Simonsson. - LUND : Studentlitteratur. - 9789144047874
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 5. |
- Hanrieder, Jörg, 1980, et al.
(författare)
-
MALDI imaging mass spectrometry: Neurochemical imaging of proteins and peptides
- 2019
-
Ingår i: Neuroproteomics. Ka Wan Li (red.). - New York, NY : Springer. - 0893-2336 .- 1940-6045. - 9781493996612 ; , s. 179-197
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- © Springer Science+Business Media, LLC, part of Springer Nature 2019. The central nervous system (CNS) constitutes the most intricate tissue in the human body. Neurological diseases, in particular, have a complex pathophysiology and are heterogeneous in their pathological and clinical presentation and therefore poorly understood on a molecular level. Increased insight in molecular CNS disease pathophysiology relates directly to the advancement of novel bioanalytical technologies that allow highly resolved, sensitive, specific, and comprehensive molecular analysis and molecular imaging in complex biological tissues, and in the CNS in particular. Imaging mass spectrometry (IMS) is an emerging technique for molecular imaging, characterized by its high molecular specificity and is therefore a powerful approach for investigating molecular localization patterns in CNS-derived tissue and cells. Over the last 20 years, IMS has been demonstrated to be a promising technology for chemical imaging in biochemical studies, but its application in clinical research is still in its infancy. The goal of this chapter is to provide the reader with a detailed step-by-step guide through the IMS workflow for the successful replication of published experimental data. Moreover, the aim is to give a concise overview of the major developments and applications of matrix-assisted laser desorption ionization (MALDI) based imaging mass spectrometry for neurochemical profiling with particular focus on protein and peptide imaging in neurodegenerative disease pathology.
|
|
| 6. |
- Lista, S, et al.
(författare)
-
Blood and cerebrospinal fluid biomarkers for Alzheimer’s disease
- 2017
-
Ingår i: Dementia. David Ames, John T. O'Brien, Alistair Burns (red.). - Boca Raton : CRC Press. - 9781498703116 ; , s. 528-538
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- In general, a biomarker denes a biological process or disease characteristic that is objectively measured (Biomarkers Denitions Working Group, 2001). Such measurements may be used for diagnostic purposes, but also to study physiological or pathophysiological mechanisms and to evaluate desired pharmacodynamic eects or side eects of pharmacological treatments. According to Biomarkers Denitions Working Group: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, the ideal biomarker for Alzheimer’s disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically con-rmed cases as well as have a diagnostic accuracy of at least 80% (e Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and National Institute on Aging Working Group, 1998). With respect to clinically relevant questions, such as detection, diagnosis, prediction and treatment of a given disease, biomarkers may serve certain distinct functions
|
|
| 7. |
- Pannee, Josef, 1979, et al.
(författare)
-
Abeta CSF LC-MS
- 2021
-
Ingår i: Cerebrospinal Fluid Biomarkers. Teunissen C.E., Zetterberg H. (eds). - New York, NY : Springer. - 0893-2336. - 9781071613184 ; , s. 55-69
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- In this chapter, a method using an antibody independent approach based on solid phase extraction (SPE) and liquid chromatography (LC)-tandem mass spectrometry (MS/MS) is described for the analysis of Aβ isoforms in cerebrospinal fluid (CSF). Stable isotope-labeled Aβ peptides are used as internal standards, enabling absolute quantification. A high-resolution quadrupole-Orbitrap hybrid instrument was used for measurements. The method allows quantification of CSF Aβ1-42 between 150 and 4000 pg/mL. © 2021, Springer Science+Business Media, LLC, part of Springer Nature.
|
|
| 8. |
- Rosén, Christoffer, 1986, et al.
(författare)
-
Alzheimer’s disease and other neurodegenerative disorders
- 2015
-
Ingår i: Cerebrospinal Fluid in Clinical Neurology. - Cham : Springer. - 9783319012254 ; , s. 329-351
-
Bokkapitel (refereegranskat)abstract
- Traditionally, patients suffering from Alzheimer’s disease (AD) have been diagnosed according to clinical criteria, and a diagnosis has only been made in the dementia stage of the disease. Defi nite diagnosis required autopsy to confi rm the neuropathological fi ndings associated with AD, namely, extracellular depositions of amyloid a (Aa) protein and intraneuronal neurofi brillary tangles consisting of hyperphosphorylated tau (P-tau) protein, together with gross cortical atrophy caused by neuronal degeneration and loss. These fi ndings are refl ected in the cerebrospinal fl uid (CSF) of patients with AD. Numerous studies have shown that AD patients have lower levels of Aa42 and higher levels of P-tau and total tau (T-tau) in CSF than cognitively healthy controls. In the new diagnostic criteria for AD, these CSF biomarkers are included as in vivo evidence of AD neuropathology together with positron emission tomography (PET) measurements of global cortical amyloid load. Further, AD is now divided into several disease stages, namely, preclinical AD and mild cognitive impairment and dementia due to AD. In this chapter, we review CSF biomarker characteristics for the various disease stages for AD and how to use them in the differentiation against other common neurodegenerative disorders. New candidate CSF biomarkers for AD are also presented, as well as a discussion on the standardization of biomarkers and their application in clinical trials. © Springer International Publishing Switzerland 2015.
|
|
| 9. |
- Simrén, Joel, 1996, et al.
(författare)
-
Fluid biomarkers in Alzheimer's disease
- 2022
-
Ingår i: Advances in Clinical Chemistry. - : Elsevier. - 0065-2423. ; , s. 249 - 281
-
Bokkapitel (refereegranskat)abstract
- Alzheimer's disease (AD) characterization has progressed from being indexed using clinical symptomatology followed by neuropathological examination at autopsy to in vivo signatures using cerebrospinal fluid (CSF) biomarkers and positron emission tomography. The core AD biomarkers reflect amyloid-β plaques (A), tau pathology (T) and neurodegeneration (N), following the ATN schedule, and are now being introduced into clinical routine practice. This is an important development, as disease-modifying treatments are now emerging. Further, there are now reproducible data on CSF biomarkers which reflect synaptic pathology, neuroinflammation and common co-pathologies. In addition, the development of ultrasensitive techniques has enabled the core CSF biomarkers of AD pathophysiology to be translated to blood (e.g., phosphorylated tau, amyloid-β and neurofilament light). In this chapter, we review where we stand with both core and novel CSF biomarkers, as well as the explosion of data on blood biomarkers. Also, we discuss potential applications in research aiming to better understand the disease, as well as possible use in routine clinical practice and therapeutic trials.
|
|
| 10. |
- Zetterberg, Henrik, 1973, et al.
(författare)
-
Biokemiska utredningar vid kognitiv sjukkdom
- 2012
-
Ingår i: Kognitiv medicin / Lars-Olof Wahlund, Christer Nilsson, Anders Wallin (red.). - Stockholm : Norstedts förlag. - 9789113023229 ; , s. 134-140
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
